---
schema_version: "secwatch.filing_event.v1"
accession: "0001129928-26-000006"
form_type: "8-K"
ticker: "ONCY"
cik: "0001129928"
company_name: "ONCOLYTICS BIOTECH INC"
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:39:34.720111+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Oncolytics prioritizes SCAC and CRC registration studies; GOBLET enrollment closed

## Summary
- Concluded enrollment in GOBLET gastrointestinal study; now focusing on registrational studies in squamous cell anal cancer (SCAC) and metastatic colorectal cancer (CRC).
- Plans to meet with FDA mid-April to align on single-arm SCAC registrational study; believes <100 subjects may be sufficient for approval.
- GOBLET Cohort 5 (PDAC) enrollment stopped at ~20 patients per arm; data to inform future PDAC strategy.
- Sufficient cash on hand to execute near-term milestones, avoiding immediate material dilution.
- GOBLET data support platform approach in GI cancers; company will follow existing Cohort 5 patients for survival data.

## SEC filing metadata
- accession: 0001129928-26-000006
- form_type: 8-K
- ticker: ONCY
- cik: 0001129928
- company_name: ONCOLYTICS BIOTECH INC
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000006/0001129928-26-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000006/oncy-20260224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001129928-26-000006
- JSON: https://secwatch.observer/filing/0001129928-26-000006.json
- Plain text: https://secwatch.observer/filing/0001129928-26-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.